Asthma UK Scotland Comment On The SMC's Approval Of Omalizumab (Xolair) For The Treatment Of Children Aged 6-12 With Severe, Allergic Asthma
Links shared publicly online about this topic.
- 1,243total visits
Asthma UK Scotland Comment On The SMC's Approval Of Omalizumab (Xolair) For The Treatment Of Children Aged 6-12 With Severe, Allergic Asthma
View full resource at medicalnewstoday.com
Tags: Allergies, Asthma, Asthma Medication, Allergic Asthma, Children's Health, Teen Health, Xolair
Most Recently Shared on April 13, 2010 at 6:15 pm By:
Asthma UK Scotland Comment On The SMC's Approval Of Omalizumab (Xolair) For The Treatment Of Children Aged 6-12 With S... http://mnt.to/3B8T
Also Shared By:
Asthma UK Comment On Final NICE Determination On Xolair For 6-11s - QualityPoint Technologies
qualitypointtech.net — “Dr Mike Thomas, Chief Medical Adviser to Asthma UK, said: 'Hundreds of children across England with the most severe, allergic asthma will now be denied a pioneering treatment that could free them from crippling daily asthma symptoms, endless trips to hospital and huge amounts of time off school. 'As the Scottish Medicines Consortium (SMC) has already approved omalizumab (Xolair) for use in children aged 6-11 in Scotland, patients will once again be faced with a treatment postcode lottery dependi” View full resource at qualitypointtech.net
Most Recently Shared on August 15, 2010 at 11:54 am By:
Asthma UK Comment On Final NICE Determination On Xolair For 6-11s: Dr Mike Thomas, Chief Medical Adviser to Asthma... http://bit.ly/9jCOE7
Advertisement
MNT Allergy News
@mnt_allergy
Asthma UK Scotland Comment On The SMC's Approval Of Omalizumab (Xolair) For The Treatment Of Children Aged 6-12 With S... http://mnt.to/3B8T
1 year ago...